Conv. Plasma
Nigella Sativa

All deuremidevir studies
Meta analysis
study COVID-19 treatment researchDeuremidevirDeuremidevir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Time to viral- 11% Improvement Relative Risk Time to viral-, ≤5 days 23% Time to viral-, >5 days -3% Deuremidevir  Shen et al.  EARLY TREATMENT Is early treatment with deuremidevir beneficial for COVID-19? Prospective study of 136 patients in China (March - March 2022) Faster viral clearance with deuremidevir (p<0.000001) Shen et al., Emerging Microbes & Infec.., Jun 2022 Favors deuremidevir Favors control

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants

Shen et al., Emerging Microbes & Infections, doi:10.1080/22221751.2022.2078230, NCT05242042
Jun 2022  
  Source   PDF   All   Meta
Prospective 136 hospitalized mild to moderate COVID-19 patients in China, showing faster viral clearance with VV116 treatment. 60 patients received VV116 300mg twice daily for 5 days plus standard care, while 76 patients received only standard care. VV116 was generally safe, with only mild adverse events reported.
time to viral-, 10.9% lower, relative time 0.89, p < 0.001, treatment mean 9.92 (±0.436) n=60, control mean 11.13 (±0.464) n=76, all patients.
time to viral-, 23.1% lower, relative time 0.77, p < 0.001, treatment mean 8.56 (±0.469) n=32, control mean 11.13 (±0.464) n=76, ≤5 days.
time to viral-, 3.0% higher, relative time 1.03, p = 0.006, treatment mean 11.46 (±0.681) n=28, control mean 11.13 (±0.464) n=76, >5 days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shen et al., 2 Jun 2022, prospective, China, peer-reviewed, mean age 33.9, 23 authors, study period 8 March, 2022 - 24 March, 2022, trial NCT05242042 (history). Contact:,
This PaperDeuremidevirAll
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
Yinzhong Shen, Jingwen Ai, Na Lin, Haocheng Zhang, Yang Li, Hongyu Wang, Sen Wang, Zhen Wang, Tao Li, Feng Sun, Zhenyu Fan, Liqun Li, Yunfei Lu, Xianmin Meng, Hong Xiao, Huiliang Hu, Yun Ling, Feng Li, Hongdi Li, Chunmei Xi, Liping Gu, Wenhong Zhang, Xiaohong Fan
Emerging Microbes & Infections, doi:10.1080/22221751.2022.2078230
Omicron variant of SARS-CoV-2 has become the predominant variant worldwide. VV116 is an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies. We conducted an open, prospective cohort study to evaluate its safety and effectiveness in Chinese participants infected with the omicron variant from March 8th, 2022 to March 24th, 2022. 136 hospitalized nonsevere patients confirmed with COVID-19 were enrolled including 60 patients who received VV116 (300 mg, BID×5 days) in the treatment group and 76 patients who didn't receive VV116 in the control group besides standard treatment. Viral load shedding time and adverse events were collected during the follow-up. There was no significant difference in baseline characteristics between the VV116 group and the control group, except for a higher symptom prevalence in the control group (P = 0.021). The median time from the first positive test to the first VV116 administration was 5 (range: 2-10) days. Participants who received VV116 within 5 days since the first positive test had a shorter viral shedding time than the control group (8.56 vs 11.13 days), and cox regression analysis showed adjusted HR of 2.37 [95%CI 1.50-3.75], P < 0.001. In symptomatic subgroup, VV116 group had a shorter viral shedding time than the control group (P = 0.016). A total of 9 adverse events with no serious adverse events were reported in the VV116 group, all of them were resolved without intervention. VV116 is a safe, effective oral antiviral drug, which shows a better performance within the early onset of omicron infection.
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med
Cao, Wang, Jian, Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies, Nature, doi:10.1038/s41586-021-04385-3
Christensen, Olsen, Long, Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with Coronavirus disease 2019 caused by the omicron variant of severe acute Respiratory syndrome Coronavirus 2 in Houston, Texas, Am J Pathol
Dejnirattisai, Huo, Zhou, SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell
Ekpanyapong, Bunchorntavakul, Reddy, COVID-19 and the liver: lessons learnt from the EAST and the WEST, A year later, J Viral Hepat
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, Nonhospitalized adults with COVID-19, N Engl J Med
Mahase, COVID-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports, Br Med J
Qian, Wang, Zhang, Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects, Acta Pharmacol Sin, doi:10.1038/s41401-022-00895-6
Spinner, Gottlieb, Criner, Effect of Remdesivir vs standard care on Clinical status at 11 days in patients With moderate COVID-19: A randomized clinical trial, JAMA
Takashita, Kinoshita, Yamayoshi, Efficacy of antiviral agents against the SARS-CoV-2 Omicron Subvariant BA.2, N Engl J Med
Vangeel, Chiu, Jonghe, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern, Antiviral Res
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, The Lancet
Xie, Yin, Zhang, Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2, Cell Res
Zhang, Shi, Wang, Liver injury in COVID-19: management and challenges, Lancet Gastroenterol Hepatol
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop